האיחוד האירופי - איטלקית - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabete mellito, tipo 2 - farmaci usati nel diabete - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , triplice terapia di associazione) in aggiunta alla dieta e all'esercizio fisico in pazienti non adeguatamente controllati il loro dosaggio massimo tollerato di metformina ed una sulfonilurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

איטליה - איטלקית - Ministero della Salute

bayer ag - tebuconazolo; - granuli idrosospensibili - 25.0 g i valori indicati sono per 100 g di prodotto. - tebuconazolo; 25% - fungicida - fungicida - (n) pericoloso per l''ambiente (xn) nocivo

האיחוד האירופי - איטלקית - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabete mellito, tipo 2 - farmaci usati nel diabete - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

האיחוד האירופי - איטלקית - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabete mellito, tipo 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 e 5. 1 per i dati disponibili su diverse combinazioni).

האיחוד האירופי - איטלקית - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabete mellito, tipo 2 - farmaci usati nel diabete - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 e 5. 1 per i dati disponibili su diverse combinazioni).

איטליה - איטלקית - AIFA (Agenzia Italiana del Farmaco)

biogaran - sitagliptin - sitagliptin

איטליה - איטלקית - AIFA (Agenzia Italiana del Farmaco)

zaklady farmaceutyczne polpharma sa - sitagliptin - sitagliptin

איטליה - איטלקית - AIFA (Agenzia Italiana del Farmaco)

adamed s.r.l. - sitagliptin - sitagliptin

איטליה - איטלקית - AIFA (Agenzia Italiana del Farmaco)

sandoz s.p.a. - sitagliptin - sitagliptin

איטליה - איטלקית - AIFA (Agenzia Italiana del Farmaco)

adamed s.r.l. - sitagliptin - sitagliptin